Adaptimmune therapeutics plc (ADAP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Jun'15Jun'14Jun'13
Cash flows from operating activities
Net loss

-137,165

-95,514

-70,138

-71,579

-22,058

-11,601

-8,740

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation

7,172

7,188

5,032

3,126

705

240

47

Amortization

838

622

391

160

30

0

0

Share-based compensation expense

11,053

16,202

10,804

8,821

7,078

332

178

Realized loss on available-for-sale debt securities

13

2,473

646

-

-

-

-

Unrealized foreign exchange gains

-1,076

-9,747

8,599

1,314

-13

-

-

Other

-185

237

341

122

-

-

-

Changes in operating assets and liabilities:
Increase in receivables and other operating assets

1,436

5,162

7,346

6,533

7,812

1,481

299

Increase in non-current operating assets

1,450

-742

-2,115

-2,221

-

-

-

Increase (decrease) in payables and deferred revenue

7,603

-40,923

12,439

16,808

-7,622

49,345

-1,860

Net cash provided by (used in) operating activities

-112,500

-104,388

-54,315

-48,168

-29,666

36,835

-10,674

Acquisition of property, plant and equipment

1,592

3,910

24,643

11,506

5,080

1,366

167

Acquisition of intangibles

1,482

798

369

1,279

-

-

-

Proceeds from disposal of property, plant and equipment

-

-

550

-

122

-

-

Maturity of short-term deposits

-

-

40,625

73,377

-

-

-

Investment in short-term deposits

-

-

18,000

42,837

53,879

-

-

Maturity or redemption of marketable securities

125,303

138,038

29,090

-

-

-

-

Investment in marketable securities

27,284

150,787

153,334

-

-

-

-

Net cash (used in) provided by investing activities

94,945

-17,457

-126,081

17,755

-58,837

-1,366

-167

Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs of $979 and $nil

-

99,653

103,167

-

-

15,812

6,599

Proceeds from issuance of preferred shares, net of issuance costs of $4,949

-

-

-

-

98,872

-

-

Proceeds from issuance of common stock upon initial public offering, net of issuance costs of $13,387

-

-

-

-

175,989

-

-

Proceeds from exercise of stock options

366

3,037

401

17

-

192

-

Net cash provided by financing activities

366

102,690

103,568

17

274,861

14,714

7,889

Bank overdraft repaid

-

-

-

-

-

-1,290

1,290

Effect of currency exchange rate changes on cash, cash equivalents and restricted cash

-372

3,335

2,328

-5,579

-8,491

996

-161

Net increase (decrease) in cash and cash equivalents

-17,568

-15,820

-74,500

-35,975

177,867

51,179

-3,113

Supplemental cash flow information
Interest received

3,426

3,114

1,784

1,191

-

-

-

Income taxes paid

201

258

1,565

34

280

-

-

Deemed dividends

-

-

-

-

14,735

-

-

Allowance for tenant improvements

-

-

-

2,607

-

-

-